Stock Track | CMS Stock Soars 8% as New Drug Application Accepted by NMPA

Stock Track09-24

Shares of China Medical System Holdings Ltd (CMS) surged 8.16% on Monday, following the company's announcement that its new drug application for a vitiligo indication of ruxolitinib phosphate cream has been accepted by the National Medical Products Administration (NMPA) of China.

The acceptance of the new drug application marks a significant milestone for CMS, as it paves the way for the potential approval and commercialization of the vitiligo treatment in the Chinese market. Vitiligo is a chronic skin condition characterized by the loss of pigmentation in patches of skin, affecting millions of people worldwide.

If approved, the ruxolitinib phosphate cream would be one of the few targeted treatments available for vitiligo, potentially addressing a significant unmet medical need. The drug's potential to provide an effective treatment option for vitiligo patients could open up a substantial market opportunity for CMS in China and beyond.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1171592440?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-24 23:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1171592440","market":"us","top_or_hot":-1,"title":"Stock Track | CMS Stock Soars 8% as New Drug Application Accepted by NMPA","media":"Stock Track","content":"<p>Shares of China Medical System Holdings Ltd (CMS) surged 8.16% on Monday, following the company's announcement that its new drug application for a vitiligo indication of ruxolitinib phosphate cream has been accepted by the National Medical Products Administration (NMPA) of China.</p>\n\n<p>The acceptance of the new drug application marks a significant milestone for CMS, as it paves the way for the potential approval and commercialization of the vitiligo treatment in the Chinese market. Vitiligo is a chronic skin condition characterized by the loss of pigmentation in patches of skin, affecting millions of people worldwide.</p>\n\n<p>If approved, the ruxolitinib phosphate cream would be one of the few targeted treatments available for vitiligo, potentially addressing a significant unmet medical need. The drug's potential to provide an effective treatment option for vitiligo patients could open up a substantial market opportunity for CMS in China and beyond.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | CMS Stock Soars 8% as New Drug Application Accepted by NMPA</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | CMS Stock Soars 8% as New Drug Application Accepted by NMPA\n</h2>\n\n<h4 class=\"meta\">\n\n2024-09-24 23:20 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of China Medical System Holdings Ltd (CMS) surged 8.16% on Monday, following the company's announcement that its new drug application for a vitiligo indication of ruxolitinib phosphate cream ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"00867","symbol_name":"康哲药业","start_time":0,"source_url":"","article_id":"1171592440","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1171592440","pubTimestamp":1727191242,"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of China Medical System Holdings Ltd  surged 8.16% on Monday, following the company's announcement that its new drug application for a vitiligo indication of ruxolitinib phosphate cream has been accepted by the National Medical Products Administration  of China.The acceptance of the new drug application marks a significant milestone for CMS, as it paves the way for the potential approval and commercialization of the vitiligo treatment in the Chinese market. Vitiligo is a chronic skin cond","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"00867":"康哲药业"},"translate_title":"股票赛道康哲药业股价飙升8%，因新药申请获NMPA受理","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00867":1},"content_text":"Shares of China Medical System Holdings Ltd (CMS) surged 8.16% on Monday, following the company's announcement that its new drug application for a vitiligo indication of ruxolitinib phosphate cream has been accepted by the National Medical Products Administration (NMPA) of China.\nThe acceptance of the new drug application marks a significant milestone for CMS, as it paves the way for the potential approval and commercialization of the vitiligo treatment in the Chinese market. Vitiligo is a chronic skin condition characterized by the loss of pigmentation in patches of skin, affecting millions of people worldwide.\nIf approved, the ruxolitinib phosphate cream would be one of the few targeted treatments available for vitiligo, potentially addressing a significant unmet medical need. The drug's potential to provide an effective treatment option for vitiligo patients could open up a substantial market opportunity for CMS in China and beyond.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1171592440"}